Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 8/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17955294 | 0.99 | TERT (0.39) | TERTGAANR1H2NR1H3PTPN1 | |
| SCHEMBL17955250 | 0.98 | GAA (0.36) | TERTGAANR1H2NR1H3PTPN1 | |
| SCHEMBL17954278 | 0.92 | GAA (0.34) | TERTGAANR1H2NR1H3PTPN1 | |
| SCHEMBL18086330 | 0.91 | TERT (0.39) | TERTNR1H2NR1H3PTPN1PPARG | |
| SCHEMBL22404704 | 0.90 | TERT (0.40) | TERTNR1H2NR1H3PPARGMTNR1A | |
| SCHEMBL22172455 | 0.90 | TERT (0.40) | TERTNR1H2NR1H3PPARGPPARD | |
| SCHEMBL20216031 | 0.89 | TERT (0.36) | TERTNR1H2NR1H3PPARGPPARD | |
| SCHEMBL17954267 | 0.88 | ITPR1 (0.32) | TERT | |
| SCHEMBL20375671 | 0.87 | MTNR1A (0.36) | TERTNR1H2NR1H3PTPN1PPARG | |
| SCHEMBL22077955 | 0.86 | HPGD (0.42) | GAAPTPN1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-10-12 | — | — | US | disclosed |
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | Arrowheads Pharmaceuticals, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220090077-A1 | RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use | Arrowhead Pharmaceuticals, Inc. | 2022-03-24 | — | — | US | disclosed |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-12-30 | — | — | US | disclosed |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-23 | — | — | US | disclosed |
| US-9932586-B2 | Compositions and methods for inhibiting gene expression of LPA | Arrowhead Pharmaceuticals, Inc. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932586-B2 | Compositions and methods for inhibiting gene expression of LPA | Arrowhead Pharmaceuticals, Inc. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170096665-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-20170096665-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | HAVCR2, ASGR1, HDGF | TERT 3632/4885GAA 1589/4885NR1H2 34/4885 |
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | TERT 3632/4885GAA 1589/4885NR1H2 34/4885 |
| US-20220090077-A1 | RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use | SCNN1A, SCNN1G, SCNN1B | TERT 3924/4885GAA 1062/4885NR1H2 3477/4885 |
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | ASGR1, LDLR, SCARB1 | TERT 3752/4885GAA 101/4885NR1H2 48/4885 |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, NR1H4 | TERT 3911/4885GAA 1743/4885NR1H2 30/4885 |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | HAVCR2, EIF2AK2, HDGF | TERT 2394/4885GAA 1489/4885NR1H2 284/4885 |
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | TERT 2165/4885GAA 292/4885NR1H2 117/4885 |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | HAVCR2, ASGR1, HDGF | TERT 3632/4885GAA 1589/4885NR1H2 34/4885 |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | RNGTT, NSUN2, NSUN3 | TERT 2544/4885GAA 2599/4885NR1H2 4571/4885 |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | SERPINA2, SERPINC1, SERPINA3 | TERT 548/4885GAA 979/4885NR1H2 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.